HCV infections are a serious threat to public health. An important drug target is the NS3 protease, for which several inhibitors are in clinical trials. Because of the high mutation rate of the virus, resistance against any HCV-specific drug is likely to become a substantial problem. Structure–activity data for the major resistant variants are therefore needed to guide future designs of protease inhibitors.
Methods
The inhibitory potency of tripeptide NS3 protease inhibitors, with either a P2 proline or phenylglycine, in combination with different P3 and P1-P1’ groups, was assessed in enzyme activity assays using the full-length NS3 protein with known resistance- conferring substitutions A156T or D168V. The results obtained from these variants were compared with the inhibition of the wild-type enzyme. Molecular modelling was used to rationalize the biochemical results.
Results
Inhibitors combining the P2 proline and P1 (1R,2S)-1-amino-2-vinylcyclopropyl-carboxylic acid (vinylACCA) lost much of their potency on the resistant variants. Exchange of the P2 proline for phenylglycine yielded inhibitors that were equipotent on the wild-type and on the A156T and D168V variants. The same result was obtained from the combination of either the P2 residue with a norvaline or an aromatic scaffold in the P1 position.
Conclusions
The combination of a substituted P2 proline and P1 vinylACCA appears to be the main problem behind the observed resistance. Molecular modelling suggests an enforced change in binding conformation for the P2 proline- based inhibitors, whereas the phenylglycine-based inhibitors retained their wild-type binding conformation in the substituted forms of the enzyme.
References
1.
ShepardC.W., FinelliL., AlterM.Global epidemiology of hepatitis C virus infection.Lancet Infect Dis2005; 5: 558–567.
2.
WebsterD.P., KlenermanP., CollierJ., JefferyK.J.M.Development of novel treatments for hepatitis C.Lancet Infect Dis2009; 9: 108–117.
3.
ZeuzemS., SchmidtJ.M., LeeJ-H, Von WagnerM., TeuberG., RothW.K.Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.Hepatology1998; 28: 245–252.
4.
NeumannA.U., LamN.P., DahariH.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.Science1998; 282: 103–107.
5.
OgataN., AlterH.J., MillerR.H., PurcellR.H.Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.Proc Natl Acad Sci U S A1991; 88: 3392–3396.
6.
OkamotoH., KojimaM., OkadaS.I.Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.Virology1992; 190: 894–899.
7.
WhiteP.W., Llinas-BrunetM., BosM.Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.Prog Med Chem2006; 44: 65–107.
8.
Trail watch: protease inhibitors show promise against HCV.Nat Rev Drug Discov2009; 8: 11.
9.
LuL., Pilot-MatiasT.J., StewartK.D.Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.Antimicrob Agents Chemother2004; 48: 2260–2266.
10.
LinC., LinK., LuongY-P. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.J Biol Chem2004; 279: 17508–17514.
11.
HeY., KingM.S., KempfD.J.Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.Antimicrob Agents Chemother2008; 52: 1101–1110.
12.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Gastroenterology2007; 132: 1767–1777.
13.
QiuP., SanforenzoV., CurryS.Identification of HCV protease inhibitor resistance mutations by selection pressure-based method.Nucleic Acids Res2009; 37: e74.
14.
CuberoM., EstebanJ.I., OteroT.Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.Virology2008; 370: 237–245.
15.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.J Infect Dis2008; 198: 800–807.
16.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients.Hepatology2008; 48: 1769–1778.
17.
GaudieriS., RauchA., PfafferottK.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Hepatology2009; 49: 1069–1082.
18.
LinC., GatesC.A., RaoB.G.In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.J Biol Chem2005; 280: 36784–36791.
19.
TongX., ChaseR., SkeltonA., ChenT., Wright-MinogueJ., MalcolmB.A.Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.Antiviral Res2006; 70: 28–38.
20.
SchechterI., BergerA.On the size of the active site in proteases. I. Papain.Biochem Biophys Res Commun1967; 27: 157–162.
21.
TrozziC., BartholomewL., CeccacciA.In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.J Virol2003; 77: 3669–3679.
22.
CourcambeckJ., BouzidiM., PerbostR.Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.Antivir Ther2006; 11: 847–855.
23.
DahlG., SandströmA., ÅkerblomE., DanielsonU.H.Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.Antivir Ther2007; 12: 733–740.
24.
RönnR., SabnisY.A., GossasT.Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3.Bioorg Med Chem2006; 14: 544–559.
25.
RönnR., GossasT., SabnisY.A.Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors.Bioorg Med Chem2007; 15: 4057–4068.
26.
RönnR., LampaA., PetersonS.D.Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.Bioorg Med Chem2008; 16: 2955–2967.
27.
ÖrtqvistP., PetersonS.D., ÅkerblomE.Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.Bioorg Med Chem2007; 15: 1448–1474.
28.
YaoN., ReichertP., TaremiS.S., ProsiseW.W., WeberP.C.Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.Structure1999; 7: 1353–1363.
29.
StillW.C., TempczykA., HawleyR.C., HendricksonT.Semianalytical treatment of solvation for molecular mechanics and dynamics.J Am Chem Soc1990; 112: 6127–6129.
30.
McMartinC., BohacekR.S.QXP: powerful, rapid computer algorithms for structure-based drug design.J Comput Aided Mol Des1997; 11: 333–344.
31.
KolossvaryI., GuidaW.C.Low Mode Search. An efficient, automated computational method for conformational analysis: application to cyclic and acyclic alkanes and cyclic peptides.J Am Chem Soc1996; 118: 5011–5019.
32.
KolossvaryI., GuidaW.C.Low-mode conformational search elucidated: application to C39H80 and flexible docking of 9-deazaguanine inhibitors into PNP.J Comput Chem1999; 20: 1671–1684.
33.
ChangG., GuidaW.C., StillW.C.An internal-coordinate Monte Carlo method for searching conformational space.J Am Chem Soc1989; 111: 4379–4386.
34.
GulnikS.V., SuvorovL.I., LiuB.kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.Biochemistry1995; 34: 9282–9287.
35.
McGaugheyG.B., GagneM., RappeA.K.π-Stacking interactions – alive and well in proteins.J Biol Chem1998; 273: 15458–15463.
